235 related articles for article (PubMed ID: 33682358)
1. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
[TBL] [Abstract][Full Text] [Related]
9. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects.
Wu M; Sun J; Wu D; Xu J; Wei J; Wang Z; Yu J; Li S; Zhang H; Ding Y
Expert Opin Investig Drugs; 2021 Jan; 30(1):77-83. PubMed ID: 33241960
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
12. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Bush J; Kawakami K; Muniz R
BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
[TBL] [Abstract][Full Text] [Related]
15. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers.
Park KR; Chung H; Yang SM; Lee S; Yoon SH; Cho JY; Jang IJ; Yu KS
Expert Opin Investig Drugs; 2017 May; 26(5):619-624. PubMed ID: 28290731
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers.
Jamshidi A; Sabzvari A; Anjidani N; Shahpari R; Badri N
Expert Opin Investig Drugs; 2020 Mar; 29(3):327-331. PubMed ID: 31985294
[No Abstract] [Full Text] [Related]
20. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
Kaur P; Chow V; Zhang N; Moxness M; Kaliyaperumal A; Markus R
Ann Rheum Dis; 2017 Mar; 76(3):526-533. PubMed ID: 27466231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]